Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: Observations from a large managed-care database

Journal of Medical Economics

Volumn 12, Issue 1, 2009, Pages 1-8

  Vekeman, Francis ^a   McKenzie, R Scott ^b   Bookhart, Brahim K ^b   Laliberté, François ^a   Mei, Sheng Duh ^c   Piech, Catherine Tak ^b   Lefebvre, Patrick ^a  

^a GROUPE D ANALYSE   (Canada)

^b Centocor Ortho Biotech Services LLC   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Darbepoetin alfa; Drug utilisation evaluation; Epoetin alfa; Erythropoiesis stimulating agents; Oncology; Treatment cost

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CONTROL GROUP; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; TREATMENT DURATION;

ANEMIA; ANTINEOPLASTIC AGENTS; DRUG COSTS; DRUG UTILIZATION; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67649655898     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802648167     Document Type: Article

References (29)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634 (Pubitemid 29479929)
2. American Association of Blood Banks, America's Blood Centers & American Red Cross. Circular of information: for the use of human blood and blood components. July 2002. Available at: http://www.aabb.org/Documents/About- Blood/ Circulars-of-Information/coi0702.pdf. [accessed June 19 2008].
3. Whitaker BI, Sullivan M. The 2005 nationwide blood collection and utilization survey report. Department of Health & Human Services. Available at: http://www.hhs.gov/bloodsafety/2005NBCUS.pdf. [accessed June 19, 2008].
4. Valley AW. Overview of cancer-related anemia: focus on potential role of darbepoetin alfa. Pharmacotherapy 2002;22(9 Pt 2):150-159S. (Pubitemid 34977824)
5. Itri LM. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Semin Oncol 2002;29(3 Suppl 8):81-87. (Pubitemid 34686700)
6. Epoetin Alfa (PROCRIT®) product package insert. Available at: http://www.procrit.com/procrit/shared/OBI/PI/ ProcritBooklet.pdf#page=1. [accessed May 21 2008].
7. Darbepoetin Alfa (Aranesp®) product package insert. Available at: http://www.aranesp.com/pdf/aranesp-PI.pdf. [accessed May 21 2008].
8. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17:66-70. (Pubitemid 34823076)
9. Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep 2004;6:297-304. (Pubitemid 39359500)
10. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of Darbepoetin Alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220. (Pubitemid 34993871)
11. Canon JL, Vansteenkiste J, Bodoky G et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-284. (Pubitemid 43264711)
12. Lefebvre P, Gosselin A, McKenzie RS et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006;22:1623-1631. (Pubitemid 44449217)
13. Duh MS, Mody SH, McKenzie RS et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organization. Clin Ther 2006;28:1443-1450. (Pubitemid 44740077)
14. List price for Procrit and Aranesp from January 2007. Medi-Span Master Data Base [MDDB].
15. Evaluation and Management, CPT No.99212 - 75th Percentile. National Fee Analyzer. Eden Prairie, MN: Ingenix, 2008:53.
16. Vadhan-Raj S, Mirtsching B, Charu V et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-138.
17. Waltzman R, Croot C, Justice GR et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-650.
18. Glaspy J, Vadhan-Raj S, Patel R et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-2297. (Pubitemid 46630659)
19. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882. (Pubitemid 32538197)
20. Gosselin A, McKenzie RS, Lefebvre P et al. Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer. P T 2006;31:594-603. (Pubitemid 44657532)
21. Mark TL, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 2005;21:1347-1354. (Pubitemid 41368565)
22. Gosselin A, Lefebvre P, Duh MS et al. Dosing patterns and transfusion use in cancer patients treated with erythropoietic agents: results of an observational study of over 8,000 patients. Blood 2005;106:872 [Abstract 3118].
23. Harley C, Muser E, Nelson M, McKenzie RS, and Piech CT. Epoetin alfa and darbepoetin alfa utilization patterns among cancer patients. Poster presented at the 40th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition December 4-8, 2005, Las Vegas, NV, USA.
24. Berger A, KallichJ, Oster G. Use of darbepoetin alfa and epoetin alfa for cancer-related anemia in clinical practice. Poster presented at the 18th International Symposium of the MASCC/ISOO meeting, June 22-24, 2006, Toronto, Canada.
25. Berger A, Edelsberg J, Kallich J, Oster G. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. Clin Ther 2008;30:206-218. (Pubitemid 351836066)
26. Anderson ER, Gibson G. Considerations in darbepoetin alfa cost and reimbursement: a model for pharmacy managers. Pharmacotherapy 2003;23:119-124S. (Pubitemid 37485301)
27. Morreale A, Plowman B, DeLattre M et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Cur Med Res Opin 2004;20:381-395. (Pubitemid 38339178)
28. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2005. Am J Health-Syst Pharm 2005;62:149-167. (Pubitemid 40674546)
29. Ben-Hamadi R, Duh MS, Aggarwal J et al. Cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. Curr Med Res Opin 2005;20:1677-1682. (Pubitemid 41509187)